Cell Culture News and Research RSS Feed - Cell Culture News and Research

UCSD researchers discover cell signaling pathway that controls initiation, progression of colorectal cancer

UCSD researchers discover cell signaling pathway that controls initiation, progression of colorectal cancer

Researchers at University of California, San Diego School of Medicine have discovered a cell signaling pathway that appears to exert some control over initiation and progression of colorectal cancer, the third leading cause of cancer-related death in the United States. A key protein in the pathway also appears to be predictive of cancer survival rates. [More]
CMC Biologics expands North American manufacturing facility with addition of Bioreactor 6Pack facility

CMC Biologics expands North American manufacturing facility with addition of Bioreactor 6Pack facility

CMC Biologics, Inc., a global leader in clinical and commercial manufacturing of monoclonal antibodies and other therapeutic proteins, announced today that, as part of its global manufacturing capacity expansion strategy, it has completed the expansion of its North American manufacturing facility in Bothell, Washington with the addition of a single-use Bioreactor 6Pack™ facility. [More]
BIOCITECH, Seine-Saint-Denis CCI announce winners of first BIOCITECH Funding Day

BIOCITECH, Seine-Saint-Denis CCI announce winners of first BIOCITECH Funding Day

BIOCITECH, the city complex for healthcare and biotechnology businesses and the Seine-Saint-Denis Chamber of Commerce and Industry (CCI), today announce the three winners of the first BIOCITECH Funding Day. [More]
New 3D cell culture system could facilitate search for therapeutic agents for Parkinson's disease

New 3D cell culture system could facilitate search for therapeutic agents for Parkinson's disease

The progressive loss of neurons in the brain of Parkinson's patients is slow yet inexorable. So far, there are no drugs that can halt this insidious process. [More]
Planning for first clinical trial of MERS-CoV vaccine candidate now underway

Planning for first clinical trial of MERS-CoV vaccine candidate now underway

Researchers from Ludwig-Maximilians-Universitaet in Munich have demonstrated, in a preclinical setting, the protective effect of a candidate vaccine directed against the coronavirus that causes Middle East Respiratory Syndrome. Planning for the first clinical trial is now underway. [More]
Florida Institute finalizes funding agreement with TransGenex Nanobiotech

Florida Institute finalizes funding agreement with TransGenex Nanobiotech

The Florida Institute for the Commercialization of Public Research announced today that it has finalized a funding agreement with TransGenex Nanobiotech, Inc., a company that is developing nano-scale technologies for novel, cost-effective diagnostic and therapeutic agents against cancers and other inflammatory diseases. [More]
Phase 3 study shows Vectibix meets primary endpoint in patients with chemorefractory wild-type KRAS mCRC

Phase 3 study shows Vectibix meets primary endpoint in patients with chemorefractory wild-type KRAS mCRC

Amgen today announced that a Phase 3 study evaluating Vectibix (panitumumab) and best supportive care (BSC) met its primary endpoint, demonstrating a statistically significant improvement in overall survival (OS) in patients with chemorefractory wild-type KRAS (exon 2) metastatic colorectal cancer (mCRC) compared to those patients treated with BSC alone. [More]
GMP grade cell cryopreservation media

GMP grade cell cryopreservation media

AMSBIO has announced the launch of GMP grade STEM-CELLBANKER® manufactured in strict compliance with Japanese, EU, US, and PICS good manufacturing practice guidelines. [More]
SynGenXTM-1000 System adopted by Anthony Nolan Cell Therapy Centre

SynGenXTM-1000 System adopted by Anthony Nolan Cell Therapy Centre

SynGen Inc., a company that focuses on the development and commercialization of instrument systems that harvest stem and progenitor cells from umbilical cord blood, bone marrow, peripheral blood, and cell culture, announced today that, after extensive review of competitive systems, The Anthony Nolan Cell Therapy Centre in Nottingham UK has chosen the SynGenXTM-1000 System and the CryoPRO Workstation to process its umbilical cord blood units. Anthony Nolan has signed a 5-year contract with Deva Medical Electronics Ltd, SynGen Inc.’s UK distributor, for the supply of SynGen’s products and all post-sales support, starting late summer 2015. [More]
Amgen to discuss data supporting Repatha BLA for high cholesterol treatment with FDA EMDAC

Amgen to discuss data supporting Repatha BLA for high cholesterol treatment with FDA EMDAC

Amgen today announced that the Company will discuss the data supporting the Repatha (evolocumab) Biologics License Application (BLA) for the treatment of high cholesterol with the U.S. Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC). [More]
New microfluidic chip could save millions of euros in drug development costs

New microfluidic chip could save millions of euros in drug development costs

Scientists in an EU-supported project have developed a microfluidic chip that simultaneously analyses the reactions of several human organ tissues when they come into contact with candidates for new drugs. [More]
FDA grants exclusivity to Flublok influenza vaccine for 12 years

FDA grants exclusivity to Flublok influenza vaccine for 12 years

Protein Sciences Corporation announced that in a rare move, the FDA is granting exclusivity to Flublok for a period of 12 years. Flublok is the first vaccine awarded this very important status, demonstrating Flublok as a unique and game changing influenza vaccine. [More]
Takara Bio Europe launches Cellartis DEF-CS Xeno-Free Culture Medium for iPS cell culture

Takara Bio Europe launches Cellartis DEF-CS Xeno-Free Culture Medium for iPS cell culture

Takara Bio Europe AB, formerly Cellartis AB, a wholly-owned subsidiary of Takara Bio Inc., announced today that it is launching an advanced cell culture medium for iPS cell culture. This chemically-defined culture medium is pre-clinical grade, free from human- and animal-derived components, and designed for efficient expansion of undifferentiated human iPS cells. [More]

Ovizio unveils new in-line suspension cell-monitoring microscope at ESACT

Ovizio Imaging System, an innovative quantitative microscopy company specializing in life science solutions, announces today the launch of its new product, the iLine F, an in-line suspension cell-monitoring microscope. [More]
Amgen starts Phase 3 study assessing the benefit of Kyprolis in patients with relapsed/refractory multiple myeloma

Amgen starts Phase 3 study assessing the benefit of Kyprolis in patients with relapsed/refractory multiple myeloma

Amgen today announced the initiation of the ARROW trial, a global Phase 3 study evaluating the benefit of Kyprolis® (carfilzomib) for Injection administered once-weekly with dexamethasone versus the current U.S. Food and Drug Administration (FDA) approved twice-weekly administration schedule in patients with relapsed and refractory multiple myeloma who have received prior treatment with bortezomib and an immunomodulatory agent (IMiD). [More]
Amgen and Merck expand collaboration for Talimogene laherparepvec-KEYTRUDA combination study

Amgen and Merck expand collaboration for Talimogene laherparepvec-KEYTRUDA combination study

Amgen and Merck, known as MSD outside the U.S. and Canada, today announced an expanded collaboration to evaluate the efficacy and safety of talimogene laherparepvec, Amgen's investigational oncolytic immunotherapy, in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in a Phase 1, open-label trial of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). [More]
Amgen announces AMG 416 Phase 3 results for treatment of secondary hyperparathyroidism in CKD patients

Amgen announces AMG 416 Phase 3 results for treatment of secondary hyperparathyroidism in CKD patients

Amgen today announced pooled data from two pivotal Phase 3, global, randomized, placebo-controlled trials evaluating AMG 416, a novel calcimimetic, for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease (CKD) receiving hemodialysis. [More]
Amgen to present clinical data on multiple blood cancer treatments at EHA 2015

Amgen to present clinical data on multiple blood cancer treatments at EHA 2015

Amgen today announced that it will present data from multiple Kyprolis (carfilzomib) for Injection, BLINCYTO (blinatumomab), oprozomib and Nplate (romiplostim)‎ studies at the 20th Congress of the European Hematology Association taking place in Vienna, June 11 - 14, 2015. [More]
Vitamin E helps build strong muscles

Vitamin E helps build strong muscles

Body builders have it right: vitamin E does help build strong muscles, and scientists appear to have figured out one important way it does it. [More]
E-cigarette liquid flavors may alter key cellular functions in lung tissue

E-cigarette liquid flavors may alter key cellular functions in lung tissue

Certain flavorings used in electronic cigarette liquid may alter important cellular functions in lung tissue, according to new research presented at the 2015 American Thoracic Society International Conference. [More]
Advertisement
Advertisement